Alterations of DNA methylome in human bladder cancer

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69 - 90; http://dx.doi.org/10.3322/caac.20107; PMID: 21296855
   PubMed Web of Science ®Google Scholar
• American Cancer Society (ACS). Cancer Facts & Figures 2013. ACS National Home Office, Atlanta, GA, 2013.
   Google Scholar
• World Health Organization (WHO). WHO report on the global tobacco epidemic, 2008: the MPOWER package. 2008.
   Google Scholar
• Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, et al, European Association of Urology (EAU). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011; 59:997 - 1008; http://dx.doi.org/10.1016/j.eururo.2011.03.017; PMID: 21458150
   PubMed Web of Science ®Google Scholar
• Carradori S, Cristini C, Secci D, Gulia C, Gentile V, Di Pierro GB. Current and emerging strategies in bladder cancer. Anticancer Agents Med Chem 2012; 12:589 - 603; http://dx.doi.org/10.2174/187152012800617768; PMID: 22043990
   PubMed Web of Science ®Google Scholar
• Prasad SM, Decastro GJ, Steinberg GD, Medscape. Urothelial carcinoma of the bladder: definition, treatment and future efforts. Nat Rev Urol 2011; 8:631 - 42; http://dx.doi.org/10.1038/nrurol.2011.144; PMID: 21989305
   PubMed Web of Science ®Google Scholar
• Kurth KH, Denis L, Bouffioux C, Sylvester R, Debruyne FM, Pavone-Macaluso M, et al. Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 1995; 31A:1840 - 6; http://dx.doi.org/10.1016/0959-8049(95)00287-S; PMID: 8541110
   PubMed Web of Science ®Google Scholar
• Allard P, Bernard P, Fradet Y, Têtu B. The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. Br J Urol 1998; 81:692 - 8; http://dx.doi.org/10.1046/j.1464-410x.1998.00628.x; PMID: 9634043
   PubMedGoogle Scholar
• Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49:466 - 5, discussion 475-7; http://dx.doi.org/10.1016/j.eururo.2005.12.031; PMID: 16442208
   PubMed Web of Science ®Google Scholar
• Cheng L, Zhang S, MacLennan GT, Williamson SR, Lopez-Beltran A, Montironi R. Bladder cancer: translating molecular genetic insights into clinical practice. Hum Pathol 2011; 42:455 - 81; http://dx.doi.org/10.1016/j.humpath.2010.07.007; PMID: 21106220
   PubMed Web of Science ®Google Scholar
• Kriegmair M, Baumgartner R, Knüchel R, Stepp H, Hofstädter F, Hofstetter A. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol 1996; 155:105 - 9, discussion 109-10; http://dx.doi.org/10.1016/S0022-5347(01)66559-5; PMID: 7490803
   PubMed Web of Science ®Google Scholar
• Denzinger S, Burger M, Walter B, Knuechel R, Roessler W, Wieland WF, et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology 2007; 69:675 - 9; http://dx.doi.org/10.1016/j.urology.2006.12.023; PMID: 17445650
   PubMed Web of Science ®Google Scholar
• Zaak D, Kriegmair M, Stepp H, Stepp H, Baumgartner R, Oberneder R, et al. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. Urology 2001; 57:690 - 4; http://dx.doi.org/10.1016/S0090-4295(00)01053-0; PMID: 11306382
   PubMed Web of Science ®Google Scholar
• Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, et al, European Association of Urology (EAU). Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011; 59:1009 - 18; http://dx.doi.org/10.1016/j.eururo.2011.03.023; PMID: 21454009
   PubMed Web of Science ®Google Scholar
• Morgan TM, Keegan KA, Clark PE. Bladder cancer. Curr Opin Oncol 2011; 23:275 - 82; http://dx.doi.org/10.1097/CCO.0b013e3283446a11; PMID: 21311329
   PubMed Web of Science ®Google Scholar
• Papanicolaou GN, Marshall VF. Urine Sediment Smears as a Diagnostic Procedure in Cancers of the Urinary Tract. Science 1945; 101:519 - 20; http://dx.doi.org/10.1126/science.101.2629.519; PMID: 17775845
   PubMed Web of Science ®Google Scholar
• Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003; 61:109 - 18, discussion 118; http://dx.doi.org/10.1016/S0090-4295(02)02136-2; PMID: 12559279
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005; 47:736 - 48; http://dx.doi.org/10.1016/j.eururo.2005.03.014; PMID: 15925067
   PubMed Web of Science ®Google Scholar
• Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol 2008; 26:646 - 51; http://dx.doi.org/10.1016/j.urolonc.2007.06.002; PMID: 18367109
   PubMed Web of Science ®Google Scholar
• Parker J, Spiess PE. Current and emerging bladder cancer urinary biomarkers. ScientificWorldJournal 2011; 11:1103 - 12; http://dx.doi.org/10.1100/tsw.2011.104; PMID: 21623456
   PubMed Web of Science ®Google Scholar
• Bhatt J, Cowan N, Protheroe A, Crew J. Recent advances in urinary bladder cancer detection. Expert Rev Anticancer Ther 2012; 12:929 - 39; http://dx.doi.org/10.1586/era.12.73; PMID: 22845408
   PubMed Web of Science ®Google Scholar
• Gakis G, Schwentner C, Todenhöfer T, Stenzl A. Current status of molecular markers for prognostication and outcome in invasive bladder cancer. BJU Int 2012; 110:233 - 7; http://dx.doi.org/10.1111/j.1464-410X.2011.10839.x; PMID: 22233187
   PubMed Web of Science ®Google Scholar
• Netto GJ, Cheng L. Emerging critical role of molecular testing in diagnostic genitourinary pathology. Arch Pathol Lab Med 2012; 136:372 - 90; http://dx.doi.org/10.5858/arpa.2011-0471-RA; PMID: 22458900
   PubMed Web of Science ®Google Scholar
• Besaratinia A, Tommasi S. Genotoxicity of tobacco smoke-derived aromatic amines and bladder cancer: current state of knowledge and future research directions. FASEB J 2013; 27:2090 - 100; http://dx.doi.org/10.1096/fj.12-227074; PMID: 23449930
   PubMed Web of Science ®Google Scholar
• Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 2011; 11:726 - 34; http://dx.doi.org/10.1038/nrc3130; PMID: 21941284
   PubMed Web of Science ®Google Scholar
• Berdasco M, Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell 2010; 19:698 - 711; http://dx.doi.org/10.1016/j.devcel.2010.10.005; PMID: 21074720
   PubMed Web of Science ®Google Scholar
• Shen H, Laird PW. Interplay between the cancer genome and epigenome. Cell 2013; 153:38 - 55; http://dx.doi.org/10.1016/j.cell.2013.03.008; PMID: 23540689
   PubMed Web of Science ®Google Scholar
• Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol 2010; 28:1057 - 68; http://dx.doi.org/10.1038/nbt.1685; PMID: 20944598
   PubMed Web of Science ®Google Scholar
• Tsai HC, Baylin SB. Cancer epigenetics: linking basic biology to clinical medicine. Cell Res 2011; 21:502 - 17; http://dx.doi.org/10.1038/cr.2011.24; PMID: 21321605
   PubMed Web of Science ®Google Scholar
• Grønbaek K, Hother C, Jones PA. Epigenetic changes in cancer. APMIS 2007; 115:1039 - 59; http://dx.doi.org/10.1111/j.1600-0463.2007.apm_636.xml.x; PMID: 18042143
   PubMed Web of Science ®Google Scholar
• Kulis M, Esteller M. DNA methylation and cancer. Adv Genet 2010; 70:27 - 56; http://dx.doi.org/10.1016/B978-0-12-380866-0.60002-2; PMID: 20920744
   PubMed Web of Science ®Google Scholar
• Laird PW. Principles and challenges of genomewide DNA methylation analysis. Nat Rev Genet 2010; 11:191 - 203; http://dx.doi.org/10.1038/nrg2732; PMID: 20125086
   PubMed Web of Science ®Google Scholar
• Rodríguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011; 17:330 - 9; http://dx.doi.org/10.1038/nm.2305; PMID: 21386836
   PubMed Web of Science ®Google Scholar
• Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002; 416:552 - 6; http://dx.doi.org/10.1038/416552a; PMID: 11932749
   PubMed Web of Science ®Google Scholar
• Gius D, Cui H, Bradbury CM, Cook J, Smart DK, Zhao S, et al. Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell 2004; 6:361 - 71; http://dx.doi.org/10.1016/j.ccr.2004.08.029; PMID: 15488759
   PubMed Web of Science ®Google Scholar
• Jacinto FV, Ballestar E, Esteller M. Impaired recruitment of the histone methyltransferase DOT1L contributes to the incomplete reactivation of tumor suppressor genes upon DNA demethylation. Oncogene 2009; 28:4212 - 24; http://dx.doi.org/10.1038/onc.2009.267; PMID: 19734945
   PubMed Web of Science ®Google Scholar
• Yang X, Lay F, Han H, Jones PA. Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci 2010; 31:536 - 46; http://dx.doi.org/10.1016/j.tips.2010.08.001; PMID: 20846732
   PubMed Web of Science ®Google Scholar
• Ibragimova I, Ibáñez de Cáceres I, Hoffman AM, Potapova A, Dulaimi E, Al-Saleem T, et al. Global reactivation of epigenetically silenced genes in prostate cancer. Cancer Prev Res (Phila) 2010; 3:1084 - 92; http://dx.doi.org/10.1158/1940-6207.CAPR-10-0039; PMID: 20699414
   PubMed Web of Science ®Google Scholar
• Chung W, Bondaruk J, Jelinek J, Lotan Y, Liang S, Czerniak B, et al. Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiol Biomarkers Prev 2011; 20:1483 - 91; http://dx.doi.org/10.1158/1055-9965.EPI-11-0067; PMID: 21586619
   PubMed Web of Science ®Google Scholar
• Wolff EM, Chihara Y, Pan F, Weisenberger DJ, Siegmund KD, Sugano K, et al. Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res 2010; 70:8169 - 78; http://dx.doi.org/10.1158/0008-5472.CAN-10-1335; PMID: 20841482
   PubMed Web of Science ®Google Scholar
• Sánchez-Carbayo M. Hypermethylation in bladder cancer: biological pathways and translational applications. Tumour Biol 2012; 33:347 - 61; http://dx.doi.org/10.1007/s13277-011-0310-2; PMID: 22274923
   PubMed Web of Science ®Google Scholar
• Momparler RL. Epigenetic therapy of cancer with 5-aza-2′-deoxycytidine (decitabine). Semin Oncol 2005; 32:443 - 51; http://dx.doi.org/10.1053/j.seminoncol.2005.07.008; PMID: 16210084
   PubMed Web of Science ®Google Scholar
• O’Rourke CJ, Knabben V, Bolton E, Moran D, Lynch T, Hollywood D, et al. Manipulating the epigenome for the treatment of urological malignancies. Pharmacol Ther 2013; 138:185 - 96; http://dx.doi.org/10.1016/j.pharmthera.2013.01.007; PMID: 23353098
   PubMed Web of Science ®Google Scholar
• Kandimalla R, van Tilborg AA, Zwarthoff EC. DNA methylation-based biomarkers in bladder cancer. Nat Rev Urol 2013; 10:327 - 35; http://dx.doi.org/10.1038/nrurol.2013.89; PMID: 23628807
   PubMed Web of Science ®Google Scholar
• Markl ID, Cheng J, Liang G, Shibata D, Laird PW, Jones PA. Global and gene-specific epigenetic patterns in human bladder cancer genomes are relatively stable in vivo and in vitro over time. Cancer Res 2001; 61:5875 - 84; PMID: 11479229
   PubMed Web of Science ®Google Scholar
• Maruyama R, Toyooka S, Toyooka KO, Harada K, Virmani AK, Zöchbauer-Müller S, et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 2001; 61:8659 - 63; PMID: 11751381
   PubMed Web of Science ®Google Scholar
• Sathyanarayana UG, Maruyama R, Padar A, Suzuki M, Bondaruk J, Sagalowsky A, et al. Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes. Cancer Res 2004; 64:1425 - 30; http://dx.doi.org/10.1158/0008-5472.CAN-03-0701; PMID: 14973053
   PubMed Web of Science ®Google Scholar
• Christoph F, Weikert S, Kempkensteffen C, Krause H, Schostak M, Miller K, et al. Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder. Int J Cancer 2006; 119:1396 - 402; http://dx.doi.org/10.1002/ijc.21971; PMID: 16642478
   PubMed Web of Science ®Google Scholar
• Hoque MO, Begum S, Topaloglu O, Chatterjee A, Rosenbaum E, Van Criekinge W, et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst 2006; 98:996 - 1004; http://dx.doi.org/10.1093/jnci/djj265; PMID: 16849682
   PubMed Web of Science ®Google Scholar
• Wolff EM, Liang G, Cortez CC, Tsai YC, Castelao JE, Cortessis VK, et al. RUNX3 methylation reveals that bladder tumors are older in patients with a history of smoking. Cancer Res 2008; 68:6208 - 14; http://dx.doi.org/10.1158/0008-5472.CAN-07-6616; PMID: 18676844
   PubMed Web of Science ®Google Scholar
• Nishiyama N, Arai E, Chihara Y, Fujimoto H, Hosoda F, Shibata T, et al. Genome-wide DNA methylation profiles in urothelial carcinomas and urothelia at the precancerous stage. Cancer Sci 2010; 101:231 - 40; http://dx.doi.org/10.1111/j.1349-7006.2009.01330.x; PMID: 19775289
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128:683 - 92; http://dx.doi.org/10.1016/j.cell.2007.01.029; PMID: 17320506
   PubMed Web of Science ®Google Scholar
• Bird A, Macleod D. Reading the DNA methylation signal. Cold Spring Harb Symp Quant Biol 2004; 69:113 - 8; http://dx.doi.org/10.1101/sqb.2004.69.113; PMID: 16117639
   PubMedGoogle Scholar
• Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358:1148 - 59; http://dx.doi.org/10.1056/NEJMra072067; PMID: 18337604
   PubMed Web of Science ®Google Scholar
• Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004; 4:143 - 53; http://dx.doi.org/10.1038/nrc1279; PMID: 14732866
   PubMed Web of Science ®Google Scholar
• Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 2008; 9:465 - 76; http://dx.doi.org/10.1038/nrg2341; PMID: 18463664
   PubMed Web of Science ®Google Scholar
• Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A 2002; 99:3740 - 5; http://dx.doi.org/10.1073/pnas.052410099; PMID: 11891299
   PubMed Web of Science ®Google Scholar
• Fernandez AF, Assenov Y, Martin-Subero JI, Balint B, Siebert R, Taniguchi H, et al. A DNA methylation fingerprint of 1628 human samples. Genome Res 2012; 22:407 - 19; http://dx.doi.org/10.1101/gr.119867.110; PMID: 21613409
   PubMed Web of Science ®Google Scholar
• Hansen KD, Timp W, Bravo HC, Sabunciyan S, Langmead B, McDonald OG, et al. Increased methylation variation in epigenetic domains across cancer types. Nat Genet 2011; 43:768 - 75; http://dx.doi.org/10.1038/ng.865; PMID: 21706001
   PubMed Web of Science ®Google Scholar
• Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev 2011; 25:1010 - 22; http://dx.doi.org/10.1101/gad.2037511; PMID: 21576262
   PubMed Web of Science ®Google Scholar
• Varley KE, Gertz J, Bowling KM, Parker SL, Reddy TE, Pauli-Behn F, et al. Dynamic DNA methylation across diverse human cell lines and tissues. Genome Res 2013; 23:555 - 67; http://dx.doi.org/10.1101/gr.147942.112; PMID: 23325432
   PubMed Web of Science ®Google Scholar
• Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983; 301:89 - 92; http://dx.doi.org/10.1038/301089a0; PMID: 6185846
   PubMed Web of Science ®Google Scholar
• Wilson AS, Power BE, Molloy PL. DNA hypomethylation and human diseases. Biochim Biophys Acta 2007; 1775:138 - 62; PMID: 17045745
   PubMed Web of Science ®Google Scholar
• Jones PA, Liang G. Rethinking how DNA methylation patterns are maintained. Nat Rev Genet 2009; 10:805 - 11; http://dx.doi.org/10.1038/nrg2651; PMID: 19789556
   PubMed Web of Science ®Google Scholar
• Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 2012; 13:484 - 92; http://dx.doi.org/10.1038/nrg3230; PMID: 22641018
   PubMed Web of Science ®Google Scholar
• Maunakea AK, Nagarajan RP, Bilenky M, Ballinger TJ, D’Souza C, Fouse SD, et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 2010; 466:253 - 7; http://dx.doi.org/10.1038/nature09165; PMID: 20613842
   PubMed Web of Science ®Google Scholar
• Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics 2009; 1:239 - 59; http://dx.doi.org/10.2217/epi.09.33; PMID: 20495664
   PubMed Web of Science ®Google Scholar
• Nagarajan RP, Costello JF. Epigenetic mechanisms in glioblastoma multiforme. Semin Cancer Biol 2009; 19:188 - 97; http://dx.doi.org/10.1016/j.semcancer.2009.02.005; PMID: 19429483
   PubMed Web of Science ®Google Scholar
• Nagarajan RP, Fouse SD, Bell RJ, Costello JF. Methods for cancer epigenome analysis. Adv Exp Med Biol 2013; 754:313 - 38; http://dx.doi.org/10.1007/978-1-4419-9967-2_15; PMID: 22956508
   PubMed Web of Science ®Google Scholar
• Estécio MR, Issa JP. Tackling the methylome: recent methodological advances in genome-wide methylation profiling. Genome Med 2009; 1:106; http://dx.doi.org/10.1186/gm106; PMID: 19930617
   PubMedGoogle Scholar
• Estécio MR, Yan PS, Ibrahim AE, Tellez CS, Shen L, Huang TH, et al. High-throughput methylation profiling by MCA coupled to CpG island microarray. Genome Res 2007; 17:1529 - 36; http://dx.doi.org/10.1101/gr.6417007; PMID: 17785535
   PubMed Web of Science ®Google Scholar
• Shen L, Kondo Y, Guo Y, Zhang J, Zhang L, Ahmed S, et al. Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet 2007; 3:2023 - 36; http://dx.doi.org/10.1371/journal.pgen.0030181; PMID: 17967063
   PubMed Web of Science ®Google Scholar
• Dudziec E, Goepel JR, Catto JW. Global epigenetic profiling in bladder cancer. Epigenomics 2011; 3:35 - 45; http://dx.doi.org/10.2217/epi.10.71; PMID: 22126151
   PubMed Web of Science ®Google Scholar
• Kim WJ, Kim YJ. Epigenetics of bladder cancer. Methods Mol Biol 2012; 863:111 - 8; http://dx.doi.org/10.1007/978-1-61779-612-8_6; PMID: 22359289
   PubMedGoogle Scholar
• Huepper WC, Wiely FH, Wolfe HD, Ranta KE, Leming MF, Blood FR. Experimental production of bladder tumors in dogs by administration of β-naphthylamine. J Ind Hyg Toxicol 1938; •••:46 - 84
   Google Scholar
• Spitz S, Maguigan WH, Dobriner K. The carcinogenic action of benzidine. Cancer 1950; 3:789 - 804; http://dx.doi.org/10.1002/1097-0142(1950)3:5<789::AID-CNCR2820030505>3.0.CO;2-U; PMID: 14772711
   PubMed Web of Science ®Google Scholar
• Walpole AL, Williams MHC, Roberts DC. Tumours of the urinary bladder in dogs after ingestion of 4-aminodiphenyl. Br J Ind Med 1954; 11:105 - 9; PMID: 13149742
   PubMedGoogle Scholar
• Wanibuchi H, Salim EI, Kinoshita A, Shen J, Wei M, Morimura K, et al. Understanding arsenic carcinogenicity by the use of animal models. Toxicol Appl Pharmacol 2004; 198:366 - 76; http://dx.doi.org/10.1016/j.taap.2003.10.032; PMID: 15276416
   PubMed Web of Science ®Google Scholar
• Kitchin KT. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol Appl Pharmacol 2001; 172:249 - 61; http://dx.doi.org/10.1006/taap.2001.9157; PMID: 11312654
   PubMed Web of Science ®Google Scholar
• Besaratinia A, Pfeifer GP. Investigating human cancer etiology by DNA lesion footprinting and mutagenicity analysis. Carcinogenesis 2006; 27:1526 - 37; http://dx.doi.org/10.1093/carcin/bgi311; PMID: 16344267
   PubMed Web of Science ®Google Scholar
• Ahmad I, Sansom OJ, Leung HY. Exploring molecular genetics of bladder cancer: lessons learned from mouse models. Dis Model Mech 2012; 5:323 - 32; http://dx.doi.org/10.1242/dmm.008888; PMID: 22422829
   PubMed Web of Science ®Google Scholar
• Washington MK, Powell AE, Sullivan R, Sundberg JP, Wright N, Coffey RJ, et al. Pathology of rodent models of intestinal cancer: progress report and recommendations. Gastroenterology 2013; 144:705 - 17; http://dx.doi.org/10.1053/j.gastro.2013.01.067; PMID: 23415801
   PubMed Web of Science ®Google Scholar
• Langdon SP. Animal modeling of cancer pathology and studying tumor response to therapy. Curr Drug Targets 2012; 13:1535 - 47; http://dx.doi.org/10.2174/138945012803530152; PMID: 22974396
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. The health consequences of smoking: a report of the Surgeon General. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA, 2004.
   Google Scholar
• Boffetta P. Tobacco smoking and risk of bladder cancer. Scand J Urol Nephrol Suppl 2008; 218:45 - 54; http://dx.doi.org/10.1080/03008880802283664; PMID: 18815916
   PubMedGoogle Scholar
• Kiriluk KJ, Prasad SM, Patel AR, Steinberg GD, Smith ND. Bladder cancer risk from occupational and environmental exposures. Urol Oncol 2012; 30:199 - 211; http://dx.doi.org/10.1016/j.urolonc.2011.10.010; PMID: 22385990
   PubMed Web of Science ®Google Scholar
• Vineis P, Pirastu R. Aromatic amines and cancer. Cancer Causes Control 1997; 8:346 - 55; http://dx.doi.org/10.1023/A:1018453104303; PMID: 9498898
   PubMed Web of Science ®Google Scholar
• Patrianakos C, Hoffman D. Chemical studies on tobacco smoke LXIV. On the analysis of aromatic amines in cigarette smoke. J Anal Chem 1979; 3:150 - 4
   Google Scholar
• D’Avanzo B, Negri E, La Vecchia C, Gramenzi A, Bianchi C, Franceschi S, et al. Cigarette smoking and bladder cancer. Eur J Cancer 1990; 26:714 - 8; http://dx.doi.org/10.1016/0277-5379(90)90124-C; PMID: 2144159
   PubMed Web of Science ®Google Scholar
• Vineis P, Esteve J, Hartge P, Hoover R, Silverman DT, Terracini B. Effects of timing and type of tobacco in cigarette-induced bladder cancer. Cancer Res 1988; 48:3849 - 52; PMID: 3378220
   PubMed Web of Science ®Google Scholar
• Bartsch H, Malaveille C, Friesen M, Kadlubar FF, Vineis P. Black (air-cured) and blond (flue-cured) tobacco cancer risk. IV: Molecular dosimetry studies implicate aromatic amines as bladder carcinogens. Eur J Cancer 1993; 29A:1199 - 207; http://dx.doi.org/10.1016/S0959-8049(05)80315-6; PMID: 8518034
   PubMed Web of Science ®Google Scholar
• Besaratinia A, Bates SE, Pfeifer GP. Mutational signature of the proximate bladder carcinogen N-hydroxy-4-acetylaminobiphenyl: inconsistency with the p53 mutational spectrum in bladder cancer. Cancer Res 2002; 62:4331 - 8; PMID: 12154037
   PubMed Web of Science ®Google Scholar
• Kadlubar FF, Beland FA, Beranek DT, Dooley KL, Heflich RH, Evans FE. Arylamine-DNA adduct formation in relation to urinary bladder carcinogenesis and Salmonella typhimurium mutagenesis. In: Sugimura T, Kondo S, Takebe H, eds. Environmental mutagens and carcinogens. New York, NY: Alan R. Liss, 1982:385-96.
   Google Scholar
• Talaska G, al-Juburi AZ, Kadlubar FF. Smoking related carcinogen-DNA adducts in biopsy samples of human urinary bladder: identification of N-(deoxyguanosin-8-yl)-4-aminobiphenyl as a major adduct. Proc Natl Acad Sci U S A 1991; 88:5350 - 4; http://dx.doi.org/10.1073/pnas.88.12.5350; PMID: 2052611
   PubMed Web of Science ®Google Scholar
• Yoon JI, Kim SI, Tommasi S, Besaratinia A. Organ specificity of the bladder carcinogen 4-aminobiphenyl in inducing DNA damage and mutation in mice. Cancer Prev Res (Phila) 2012; 5:299 - 308; http://dx.doi.org/10.1158/1940-6207.CAPR-11-0309; PMID: 22086680
   PubMed Web of Science ®Google Scholar
• Thompson PA, DeMarini DM, Kadlubar FF, McClure GY, Brooks LR, Green BL, et al. Evidence for the presence of mutagenic arylamines in human breast milk and DNA adducts in exfoliated breast ductal epithelial cells. Environ Mol Mutagen 2002; 39:134 - 42; http://dx.doi.org/10.1002/em.10067; PMID: 11921181
   PubMed Web of Science ®Google Scholar
• Zayas B, Stillwell SW, Wishnok JS, Trudel LJ, Skipper P, Yu MC, et al. Detection and quantification of 4-ABP adducts in DNA from bladder cancer patients. Carcinogenesis 2007; 28:342 - 9; http://dx.doi.org/10.1093/carcin/bgl142; PMID: 16926175
   PubMed Web of Science ®Google Scholar
• Faraglia B, Chen SY, Gammon MD, Zhang Y, Teitelbaum SL, Neugut AI, et al. Evaluation of 4-aminobiphenyl-DNA adducts in human breast cancer: the influence of tobacco smoke. Carcinogenesis 2003; 24:719 - 25; http://dx.doi.org/10.1093/carcin/bgg013; PMID: 12727801
   PubMed Web of Science ®Google Scholar
• Besaratinia A, Pfeifer GP. DNA damage and mutagenesis induced by polycyclic aromatic hydrocarbons. In: Luch A, ed. The carcinogenic effects of polycyclic aromatic hydrocarbons. London, UK: Imperial College Press, 2005:171-210.
   Google Scholar
• Luch A. Nature and nurture - lessons from chemical carcinogenesis. Nat Rev Cancer 2005; 5:113 - 25; http://dx.doi.org/10.1038/nrc1546; PMID: 15660110
   PubMed Web of Science ®Google Scholar
• Poirier MC. Chemical-induced DNA damage and human cancer risk. Nat Rev Cancer 2004; 4:630 - 7; http://dx.doi.org/10.1038/nrc1410; PMID: 15286742
   PubMed Web of Science ®Google Scholar
• International Agency for Research on Cancer (IARC). Some aromatic amines, hydrazine and related substances, N-nitroso compounds and miscellaneous alkylating agents. 2-Naphthylamine. Lyon (France), 1974:97-111.
   Google Scholar
• Parkes HG, Evans AEJ. Epidemiology of aromatic amine cancers. In: Searle CE, ed. Chemical carcinogens. Washington D.C.: American Chemical Society, 1984:277-301.
   Google Scholar
• Steineck G, Plato N, Norell SE, Hogstedt C. Urothelial cancer and some industry-related chemicals: an evaluation of the epidemiologic literature. Am J Ind Med 1990; 17:371 - 91; http://dx.doi.org/10.1002/ajim.4700170310; PMID: 2407118
   PubMed Web of Science ®Google Scholar
• Carthew RW, Sontheimer EJ. Origins and Mechanisms of miRNAs and siRNAs. Cell 2009; 136:642 - 55; http://dx.doi.org/10.1016/j.cell.2009.01.035; PMID: 19239886
   PubMed Web of Science ®Google Scholar
• Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Annu Rev Med 2009; 60:167 - 79; http://dx.doi.org/10.1146/annurev.med.59.053006.104707; PMID: 19630570
   PubMed Web of Science ®Google Scholar
• Winter J, Diederichs S. MicroRNA biogenesis and cancer. Methods Mol Biol 2011; 676:3 - 22; http://dx.doi.org/10.1007/978-1-60761-863-8_1; PMID: 20931386
   PubMedGoogle Scholar
• Lee Y, Jeon K, Lee JT, Kim S, Kim VN. MicroRNA maturation: stepwise processing and subcellular localization. EMBO J 2002; 21:4663 - 70; http://dx.doi.org/10.1093/emboj/cdf476; PMID: 12198168
   PubMed Web of Science ®Google Scholar
• Davis-Dusenbery BN, Hata A. Mechanisms of control of microRNA biogenesis. J Biochem 2010; 148:381 - 92; PMID: 20833630
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281 - 97; http://dx.doi.org/10.1016/S0092-8674(04)00045-5; PMID: 14744438
   PubMed Web of Science ®Google Scholar
• Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 2011; 39:Database issue D152 - 7; http://dx.doi.org/10.1093/nar/gkq1027; PMID: 21037258
   PubMed Web of Science ®Google Scholar
• Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120:15 - 20; http://dx.doi.org/10.1016/j.cell.2004.12.035; PMID: 15652477
   PubMed Web of Science ®Google Scholar
• Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435:834 - 8; http://dx.doi.org/10.1038/nature03702; PMID: 15944708
   PubMed Web of Science ®Google Scholar
• Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19:92 - 105; http://dx.doi.org/10.1101/gr.082701.108; PMID: 18955434
   PubMed Web of Science ®Google Scholar
• Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005; 433:769 - 73; http://dx.doi.org/10.1038/nature03315; PMID: 15685193
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6:259 - 69; http://dx.doi.org/10.1038/nrc1840; PMID: 16557279
   PubMed Web of Science ®Google Scholar
• Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10:704 - 14; http://dx.doi.org/10.1038/nrg2634; PMID: 19763153
   PubMed Web of Science ®Google Scholar
• Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011; 12:861 - 74; http://dx.doi.org/10.1038/nrg3074; PMID: 22094949
   PubMed Web of Science ®Google Scholar
• Ventura A, Jacks T. MicroRNAs and cancer: short RNAs go a long way. Cell 2009; 136:586 - 91; http://dx.doi.org/10.1016/j.cell.2009.02.005; PMID: 19239879
   PubMed Web of Science ®Google Scholar
• Fabbri M, Calin GA. Epigenetics and miRNAs in human cancer. Adv Genet 2010; 70:87 - 99; http://dx.doi.org/10.1016/B978-0-12-380866-0.60004-6; PMID: 20920746
   PubMed Web of Science ®Google Scholar
• Davalos V, Esteller M. MicroRNAs and cancer epigenetics: a macrorevolution. Curr Opin Oncol 2010; 22:35 - 45; http://dx.doi.org/10.1097/CCO.0b013e328333dcbb; PMID: 19907325
   PubMed Web of Science ®Google Scholar
• Ayala de la Peña F, Kanasaki K, Kanasaki M, Tangirala N, Maeda G, Kalluri R. Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinoma. J Biol Chem 2011; 286:20778 - 87; http://dx.doi.org/10.1074/jbc.M110.198069; PMID: 21388952
   PubMed Web of Science ®Google Scholar
• Dyrskjøt L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R, et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res 2009; 69:4851 - 60; http://dx.doi.org/10.1158/0008-5472.CAN-08-4043; PMID: 19487295
   PubMed Web of Science ®Google Scholar
• Han Y, Chen J, Zhao X, Liang C, Wang Y, Sun L, et al. MicroRNA expression signatures of bladder cancer revealed by deep sequencing. PLoS One 2011; 6:e18286; http://dx.doi.org/10.1371/journal.pone.0018286; PMID: 21464941
   PubMed Web of Science ®Google Scholar
• Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K, et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer 2009; 125:345 - 52; http://dx.doi.org/10.1002/ijc.24390; PMID: 19378336
   PubMed Web of Science ®Google Scholar
• Catto JW, Miah S, Owen HC, Bryant H, Myers K, Dudziec E, et al. Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res 2009; 69:8472 - 81; http://dx.doi.org/10.1158/0008-5472.CAN-09-0744; PMID: 19843843
   PubMed Web of Science ®Google Scholar
• Neely LA, Rieger-Christ KM, Neto BS, Eroshkin A, Garver J, Patel S, et al. A microRNA expression ratio defining the invasive phenotype in bladder tumors. Urol Oncol 2010; 28:39 - 48; http://dx.doi.org/10.1016/j.urolonc.2008.06.006; PMID: 18799331
   PubMed Web of Science ®Google Scholar
• Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, et al. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 2009; 15:5060 - 72; http://dx.doi.org/10.1158/1078-0432.CCR-08-2245; PMID: 19671845
   PubMed Web of Science ®Google Scholar
• Yamada Y, Enokida H, Kojima S, Kawakami K, Chiyomaru T, Tatarano S, et al. MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci 2011; 102:522 - 9; http://dx.doi.org/10.1111/j.1349-7006.2010.01816.x; PMID: 21166959
   PubMed Web of Science ®Google Scholar
• Miah S, Dudziec E, Drayton RM, Zlotta AR, Morgan SL, Rosario DJ, et al. An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer. Br J Cancer 2012; 107:123 - 8; http://dx.doi.org/10.1038/bjc.2012.221; PMID: 22644299
   PubMed Web of Science ®Google Scholar
• Saito Y, Jones PA. Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle 2006; 5:2220 - 2; http://dx.doi.org/10.4161/cc.5.19.3340; PMID: 17012846
   PubMed Web of Science ®Google Scholar
• Vogt M, Munding J, Grüner M, Liffers ST, Verdoodt B, Hauk J, et al. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch 2011; 458:313 - 22; http://dx.doi.org/10.1007/s00428-010-1030-5; PMID: 21225432
   PubMed Web of Science ®Google Scholar
• Zhu J, Jiang Z, Gao F, Hu X, Zhou L, Chen J, et al. A systematic analysis on DNA methylation and the expression of both mRNA and microRNA in bladder cancer. PLoS One 2011; 6:e28223; http://dx.doi.org/10.1371/journal.pone.0028223; PMID: 22140553
   PubMedGoogle Scholar
• Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006; 9:435 - 43; http://dx.doi.org/10.1016/j.ccr.2006.04.020; PMID: 16766263
   PubMed Web of Science ®Google Scholar
• Dudziec E, Miah S, Choudhry HM, Owen HC, Blizard S, Glover M, et al. Hypermethylation of CpG islands and shores around specific microRNAs and mirtrons is associated with the phenotype and presence of bladder cancer. Clin Cancer Res 2011; 17:1287 - 96; http://dx.doi.org/10.1158/1078-0432.CCR-10-2017; PMID: 21138856
   PubMed Web of Science ®Google Scholar
• Wiklund ED, Bramsen JB, Hulf T, Dyrskjøt L, Ramanathan R, Hansen TB, et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer 2011; 128:1327 - 34; http://dx.doi.org/10.1002/ijc.25461; PMID: 20473948
   PubMed Web of Science ®Google Scholar
• Shimizu T, Suzuki H, Nojima M, Kitamura H, Yamamoto E, Maruyama R, et al. Methylation of a panel of microRNA genes is a novel biomarker for detection of bladder cancer. Eur Urol 2013; 63:1091 - 100; http://dx.doi.org/10.1016/j.eururo.2012.11.030; PMID: 23200812
   PubMed Web of Science ®Google Scholar
• Yoshitomi T, Kawakami K, Enokida H, Chiyomaru T, Kagara I, Tatarano S, et al. Restoration of miR-517a expression induces cell apoptosis in bladder cancer cell lines. Oncol Rep 2011; 25:1661 - 8; PMID: 21479368
   PubMed Web of Science ®Google Scholar
• Yoshino H, Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Nishiyama K, et al. The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br J Cancer 2011; 104:808 - 18; http://dx.doi.org/10.1038/bjc.2011.23; PMID: 21304530
   PubMed Web of Science ®Google Scholar
• Liep J, Rabien A, Jung K. Feedback networks between microRNAs and epigenetic modifications in urological tumors. Epigenetics 2012; 7:315 - 25; http://dx.doi.org/10.4161/epi.19464; PMID: 22414795
   PubMed Web of Science ®Google Scholar
• Schaefer A, Stephan C, Busch J, Yousef GM, Jung K. Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors. Nat Rev Urol 2010; 7:286 - 97; http://dx.doi.org/10.1038/nrurol.2010.45; PMID: 20368743
   PubMed Web of Science ®Google Scholar
• Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429:457 - 63; http://dx.doi.org/10.1038/nature02625; PMID: 15164071
   PubMed Web of Science ®Google Scholar
• Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol 2010; 28:1069 - 78; http://dx.doi.org/10.1038/nbt.1678; PMID: 20944599
   PubMed Web of Science ®Google Scholar
• Mund C, Lyko F. Epigenetic cancer therapy: Proof of concept and remaining challenges. Bioessays 2010; 32:949 - 57; http://dx.doi.org/10.1002/bies.201000061; PMID: 21154865
   PubMed Web of Science ®Google Scholar
• Hashimoto H, Vertino PM, Cheng X. Molecular coupling of DNA methylation and histone methylation. Epigenomics 2010; 2:657 - 69; http://dx.doi.org/10.2217/epi.10.44; PMID: 21339843
   PubMed Web of Science ®Google Scholar
• Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 2008; 123:8 - 13; http://dx.doi.org/10.1002/ijc.23607; PMID: 18425818
   PubMed Web of Science ®Google Scholar
• Gray SG, Ekström TJ. The human histone deacetylase family. Exp Cell Res 2001; 262:75 - 83; http://dx.doi.org/10.1006/excr.2000.5080; PMID: 11139331
   PubMed Web of Science ®Google Scholar
• Zhou VW, Goren A, Bernstein BE. Charting histone modifications and the functional organization of mammalian genomes. Nat Rev Genet 2011; 12:7 - 18; http://dx.doi.org/10.1038/nrg2905; PMID: 21116306
   PubMed Web of Science ®Google Scholar
• Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 2007; 26:5310 - 8; http://dx.doi.org/10.1038/sj.onc.1210599; PMID: 17694074
   PubMed Web of Science ®Google Scholar
• Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 27:5459 - 68; http://dx.doi.org/10.1200/JCO.2009.22.1291; PMID: 19826124
   PubMed Web of Science ®Google Scholar
• Mercurio C, Minucci S, Pelicci PG. Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol Res 2010; 62:18 - 34; http://dx.doi.org/10.1016/j.phrs.2010.02.010; PMID: 20219679
   PubMed Web of Science ®Google Scholar
• Sachs MD, Ramamurthy M, Poel Hv, Wickham TJ, Lamfers M, Gerritsen W, et al. Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells. Cancer Gene Ther 2004; 11:477 - 86; http://dx.doi.org/10.1038/sj.cgt.7700726; PMID: 15118762
   PubMed Web of Science ®Google Scholar
• Pong RC, Roark R, Ou JY, Fan J, Stanfield J, Frenkel E, et al. Mechanism of increased coxsackie and adenovirus receptor gene expression and adenovirus uptake by phytoestrogen and histone deacetylase inhibitor in human bladder cancer cells and the potential clinical application. Cancer Res 2006; 66:8822 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-05-4672; PMID: 16951199
   PubMed Web of Science ®Google Scholar
• Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26:5541 - 52; http://dx.doi.org/10.1038/sj.onc.1210620; PMID: 17694093
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Santos FP, Garcia-Manero G. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 2011; 25:226 - 35; http://dx.doi.org/10.1038/leu.2010.276; PMID: 21116282
   PubMed Web of Science ®Google Scholar
• Brown BD, Naldini L. Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat Rev Genet 2009; 10:578 - 85; http://dx.doi.org/10.1038/nrg2628; PMID: 19609263
   PubMed Web of Science ®Google Scholar
• Kota J, Chivukula RR, O’Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009; 137:1005 - 17; http://dx.doi.org/10.1016/j.cell.2009.04.021; PMID: 19524505
   PubMed Web of Science ®Google Scholar
• Esau CC. Inhibition of microRNA with antisense oligonucleotides. Methods 2008; 44:55 - 60; http://dx.doi.org/10.1016/j.ymeth.2007.11.001; PMID: 18158133
   PubMed Web of Science ®Google Scholar
• Krützfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature 2005; 438:685 - 9; http://dx.doi.org/10.1038/nature04303; PMID: 16258535
   PubMed Web of Science ®Google Scholar
• Robert C, Rassool FV. HDAC inhibitors: roles of DNA damage and repair. Adv Cancer Res 2012; 116:87 - 129; PMID: 23088869
   PubMed Web of Science ®Google Scholar
• Elmén J, Lindow M, Schütz S, Lawrence M, Petri A, Obad S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008; 452:896 - 9; http://dx.doi.org/10.1038/nature06783; PMID: 18368051
   PubMed Web of Science ®Google Scholar
• Guil S, Esteller M. DNA methylomes, histone codes and miRNAs: tying it all together. Int J Biochem Cell Biol 2009; 41:87 - 95; http://dx.doi.org/10.1016/j.biocel.2008.09.005; PMID: 18834952
   PubMed Web of Science ®Google Scholar
• Gal-Yam EN, Saito Y, Egger G, Jones PA. Cancer epigenetics: modifications, screening, and therapy. Annu Rev Med 2008; 59:267 - 80; http://dx.doi.org/10.1146/annurev.med.59.061606.095816; PMID: 17937590
   PubMed Web of Science ®Google Scholar
• Cherblanc F, Chapman-Rothe N, Brown R, Fuchter MJ. Current limitations and future opportunities for epigenetic therapies. Future Med Chem 2012; 4:425 - 46; http://dx.doi.org/10.4155/fmc.12.7; PMID: 22416773
   PubMed Web of Science ®Google Scholar
• Popovic R, Licht JD. Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov 2012; 2:405 - 13; http://dx.doi.org/10.1158/2159-8290.CD-12-0076; PMID: 22588878
   PubMed Web of Science ®Google Scholar
• Azad N, Zahnow CA, Rudin CM, Baylin SB. The future of epigenetic therapy in solid tumours–lessons from the past. Nature reviews. Clin Oncol 2013; 10:256 - 66
   Web of Science ®Google Scholar
• Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012; 150:12 - 27; http://dx.doi.org/10.1016/j.cell.2012.06.013; PMID: 22770212
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646 - 74; http://dx.doi.org/10.1016/j.cell.2011.02.013; PMID: 21376230
   PubMed Web of Science ®Google Scholar
• Han H, Wolff EM, Liang G. Epigenetic alterations in bladder cancer and their potential clinical implications. Adv Urol 2012; 2012:546917; http://dx.doi.org/10.1155/2012/546917; PMID: 22829811
   PubMedGoogle Scholar